AKE-1018 / Akelos - LARVOL DELTA

Akelos Inc. Announces United States Patent and Trademark Office Allowance of Patent Claiming its Lead Compound (EIN News) - “Akelos Inc…announces that the United States Patent and Trademark Office has allowed a patent application (17/254,787) with claims covering a number of compounds including its lead compound and their pharmaceutical compositions. The patent application covers inventions made at Weill Cornell Medicine by Peter Goldstein, MD, Professor of Anesthesiology, and his group. It is licensed exclusively to Akelos. This patent allowance is an important milestone for Akelos on its path towards commercialization of a new non-opioid painkiller that will alleviate suffering and help address the opioid epidemic….‘We are delighted to announce that the patent for our lead compound for the treatment of peripheral neuropathic pain, AKE-1018, has been formally approved by the US Patent Office...The protection that the patent affords will enable us to continue to develop this product, as well as next generation therapeutics.'"

Patent • CNS Disorders • Pain • Peripheral Neuropathic Pain